Elnashar Magdy, Vaccarezza Mauro, Al-Salami Hani
Biotechnology & Drug Development Research Laboratory, School of Pharmacy & Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia.
Centre of Excellence, Department of Polymers, National Research Centre, Cairo, Egypt.
Future Sci OA. 2020 Nov 23;7(3):FSO660. doi: 10.2144/fsoa-2020-0105.
There are approximately 1 billion prediabetic people worldwide, and the global cost for diabetes mellitus (DM) is estimated to be $825 billion. In regard to Type 1 DM, transplanting a whole pancreas or its islets has gained the attention of researchers in the last few decades. Recent studies showed that islet transplantation (ILT) containing insulin-producing β cells is the most notable advancement cure for Type 1 DM. However, this procedure has been hindered by shortage and lack of sufficient islet donors and the need for long-term immunosuppression of any potential graft rejection. The strategy of encapsulation may avoid the rejection of stem-cell-derived allogeneic islets or xenogeneic islets. This review article describes various biotechnology features in encapsulation-of-islet-cell therapy for humans, including the use of bile acids.
全球约有10亿人处于糖尿病前期，全球糖尿病（DM）的成本估计为8250亿美元。关于1型糖尿病，在过去几十年中，移植整个胰腺或其胰岛已引起研究人员的关注。最近的研究表明，含有产生胰岛素的β细胞的胰岛移植（ILT）是治疗1型糖尿病最显著的进展性疗法。然而，该手术受到胰岛供体短缺和不足以及对任何潜在移植物排斥进行长期免疫抑制的需求的阻碍。封装策略可能避免干细胞衍生的同种异体胰岛或异种胰岛的排斥。这篇综述文章描述了用于人类的胰岛细胞治疗封装中的各种生物技术特性，包括胆汁酸的使用。
